Head-to-head · Cost-Efficiency Index
CoreAge Rx vs REMEVi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxREMEVi
Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1.
Visit REMEViThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 80. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. REMEVi still earns a B− — Cost-first shoppers who want bilingual, LegitScript-certified compounded GLP-1.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | REMEVi |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 80/100 |
| Semaglutide / mo | $99/mo | $219/mo |
| Tirzepatide / mo | $149/mo | $319/mo |
| Semaglutide / yr (modeled) | $1,188 | $2,628 |
| Tirzepatide / yr (modeled) | $1,788 | $3,828 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #1 | #33 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 381 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
REMEVi
80/100Where the value is
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
The tradeoffs
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.